1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: SPRI-P04445, EU-20654, NCT00266799, SPRI-PELICAN
|
|
2.
|
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LITE Randomized Pilot Study, NCT00531973
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DOXIL-BCA-3001, NCT00091442
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MITO-8, EudraCT number: 2008-001755-22, NCT00657878
|
|
5.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SWS-SAKK-92/08, SAKK 92/08, EU-20978, NCT00992706
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: AECM-0504007857, NCI-7229, 7229, NCT00182767
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CPMC-AAAB6443, NCT00334932
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ONC-2005-001, EUDRACT 2005-004569-40, NCT00289809
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UWCC-UW-6139, 6139, UW CC-05-9209-H/D, FHCRC-6139, NCT00331552
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IRB# 575-03, NCT00456989
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2007.098, NCT00724568
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-15399, IRB 106692, Millennium X05248, Ortho Biotech DOXILMMY2008, NCT00750815
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0711003269, NCT00785798
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: UWCC-6817, UWCC-6817, IR-6817, FHCRC-6817, NCT00849251
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00083, EUDRACT no 2008-0005557-38, NCT00862836
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: J0963, NA_00028490, NCT00949325
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UTHSC-MS-96205, NCI-V97-1356, NCT00003135
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: NCRR
Protocol IDs: NCRR-M01RR00030-0156, M01RR00030, NCT00006433
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0504007841, NCT00148317
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DO03-21-005, NCT00159094
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: NCI
Protocol IDs: MSKCC-04047, NCT00255723
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-05098, NCT00255801
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SEGO_DOXIL_CONS2005, NCT00248248
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: Myocet 008 (L017), NCT00250874
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-078, NCT00307294
|
